Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WL1006
- Development stage
- Unknown
- Lead developer
- Shanghai World Leader Pharmaceutical
- Modality
- Peptides
- Administration
- Intranasal
01
Overview
WL1006 is an intranasal formulation of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, being developed by Shanghai World Leader Pharmaceutical Co., Ltd. for the treatment of obesity and overweight conditions. As a GLP-1 receptor agonist, it mimics the action of the endogenous hormone to enhance insulin secretion, suppress glucagon release, and slow gastric emptying, while also acting on brain centers to increase satiety and reduce appetite. This nasal spray delivery system is designed as a non-invasive alternative to subcutaneous injections, aiming to improve patient compliance and convenience for long-term weight management. It is currently undergoing Phase I clinical evaluation for safety, tolerability, and pharmacokinetics.
- Other names
- Semaglutide Nasal Spray
02
Targets
Beyond the preview
Go deeper on WL1006.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WL1006.